Publications by authors named "Krogh N"
Background: In patients with severe asthma, treatment with anti-interleukin-5 (IL-5) biologics can lead to a reduction in fractional exhaled nitric oxide (FeNO) in some patients. The clinical implications of varying FeNO responses to anti-IL-5 biologics remain unclear. This study aims to categorise patients based on their FeNO response to anti-IL-5 biologics and evaluate the association of these categories with clinical outcomes.
View Article and Find Full Text PDFAims: Personalised medicine in chronic complex diseases such as rheumatoid arthritis (RA) is within reach but requires international multi-stakeholder collaboration. We exemplify how national implementations of the General Data Protection Regulation (GDPR) have introduced administrative delays and created disincentives for data sharing and collaborative research.
Methods: Our Danish/Swedish/Norwegian research collaboration (the 3-year NordForsk-funded "NORA" project) aims to develop a personalised medicine approach for the management of RA, built on the exploitation of unique existing data sources: longitudinal data from clinical rheumatology registries, research cohorts, nationwide health care registries, and biobank material from >20 sample collections.
Article Synopsis
- The study investigates the north-south gradient hypothesis, suggesting that individuals with rheumatoid arthritis (RA) in southern regions (like Turkey) tend to have a younger age of onset and milder disease than those in northern regions (like Denmark).
- In a comparison of 223 treatment-naïve RA patients from Denmark and Turkey, it was found that Danish patients had a later onset age (60 years) and more severe joint symptoms compared to Turkish patients (51 years).
- The findings support the hypothesis and reveal that Danish patients have more genetic risk factors for RA, prompting the need for future research into the genetic and environmental influences on these regional differences.
Article Synopsis
- The study aimed to analyze how damage from idiopathic inflammatory myopathies (IIM) changes over time and its relationship with different autoantibody subgroups using data from a large patient registry.
- Researchers examined data from 757 patients classified by their autoantibody profiles and found that damage increased over the years, with varying rates depending on the type of autoantibody present.
- Results indicated that patients with dermatomyositis-specific autoantibodies exhibited less damage per year, while those with anti-PM/Scl autoantibodies experienced greater damage, highlighting significant differences among the groups over a five-year follow-up.
In cell biology, ribosomal RNA (rRNA) 2'-methyl (2'--Me) is the most prevalent posttranscriptional chemical modification contributing to ribosome heterogeneity. The modification involves a family of small nucleolar RNAs (snoRNAs) and is specified by box C/D snoRNAs (SNORDs). Given the importance of ribosome biogenesis for skeletal muscle growth, we asked if rRNA 2'--Me in nascent ribosomes synthesized in response to a growth stimulus is an unrecognized mode of ribosome heterogeneity in muscle.
View Article and Find Full Text PDFArticle Synopsis
- The study looked at patients with PsA (psoriatic arthritis) who started a 2nd or 3rd TNFi (a type of medicine) and how many continued taking it after a year.
- Out of the patients studied, about 68% stayed on their 2nd TNFi and 66% on their 3rd TNFi after a year.
- The results showed that effectiveness of the new medicine depended on why they stopped taking the previous one, with better outcomes for those who stopped because the first medicine didn’t work as well after some time.
Objective: To investigate whether a 2-year MRI treat-to-target strategy targeting the absence of osteitis combined with clinical remission, compared with a conventional treat-to-target strategy targeting clinical remission only (IMAGINE-rheumatoid arthritis (RA) trial) improves clinical and radiographic outcomes over 5 years in patients with RA in clinical remission.
Methods: IMAGINE-more was an observational extension study of the original 2-year IMAGINE-RA randomised trial (NCT01656278). Clinical examinations and radiographs (hands and feet) were obtained yearly.
Regulation of RNA helicase activity, often accomplished by protein cofactors, is essential to ensure target specificity within the complex cellular environment. The largest family of RNA helicase cofactors are the G-patch proteins, but the cognate RNA helicases and cellular functions of numerous human G-patch proteins remain elusive. Here, we discover that GPATCH4 is a stimulatory cofactor of DHX15 that interacts with the DEAH box helicase in the nucleolus via residues in its G-patch domain.
View Article and Find Full Text PDFObjective: Patients with axial spondyloarthritis (axSpA) in clinical remission tapered tumor necrosis factor inhibitor (TNFi) therapy according to a clinical guideline. Over a 2-year follow-up period, we aimed to investigate flare frequency, dose at which flare occurred, type of flare, and predictors thereof.
Methods: Patients in clinical remission (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] < 40, physician global score < 40, and without disease activity the previous year) tapered TNFi to two-thirds the standard dose at baseline, half at week 16, one-third at week 32, and discontinued at week 48.
Article Synopsis
- This study aimed to evaluate how effective tumor necrosis factor inhibitors (TNFi) are for patients with axial spondyloarthritis (axSpA), focusing on those in their second or third series of TNFi treatment and why they switched medications (due to lack of efficacy or adverse events).
- Data from 12 European registries was analyzed, showing that 12-month retention rates for second and third TNFi were similar (71%), but six-month remission rates were higher for the second TNFi (23%) compared to the third (16%).
- Patients who discontinued their first TNFi due to adverse events had better remission rates on the second TNFi compared to those who switched due to lack
Objectives: To compare clinical characteristics, including the frequency of cutaneous, extramuscular manifestations and malignancy, between adults with anti-synthetase syndrome (ASyS) and DM.
Methods: Using data regarding adults from the MYONET registry, a cohort of DM patients with anti-Mi2/-TIF1γ/-NXP2/-SAE/-MDA5 autoantibodies, and a cohort of ASyS patients with anti-tRNA synthetase autoantibodies (anti-Jo1/-PL7/-PL12/-OJ/-EJ/-Zo/-KS) were identified. Patients with DM sine dermatitis or with discordant dual autoantibody specificities were excluded.
Article Synopsis
- - The study focuses on the importance of data harmonisation in precision medicine for rheumatoid arthritis (RA) to better understand treatment outcomes and remission rates across various treatment methods and countries.
- - Researchers analyzed data from multiple clinical registers and a trial across Sweden, Denmark, and Norway, categorizing treatment cohorts and assessing factors like treatment response and remission definitions over 36 months.
- - Findings showed high retention rates but low remission rates (less than 33% for most treatments), highlighting a significant need for improved treatment strategies in RA.
Protein N-terminal (Nt) acetylation is one of the most abundant modifications in eukaryotes, covering ~50-80 % of the proteome, depending on species. Cells with defective Nt-acetylation display a wide array of phenotypes such as impaired growth, mating defects and increased stress sensitivity. However, the pleiotropic nature of these effects has hampered our understanding of the functional impact of protein Nt-acetylation.
View Article and Find Full Text PDFTranslational regulation impacts both pluripotency maintenance and cell differentiation. To what degree the ribosome exerts control over this process remains unanswered. Accumulating evidence has demonstrated heterogeneity in ribosome composition in various organisms.
View Article and Find Full Text PDFBackground: Evaluation of effectiveness and safety of new systemic treatments for atopic dermatitis (AD) after approval is important. There are few published data exceeding 52-week therapy with dupilumab.
Objectives: To examine the safety, effectiveness and drug survival of dupilumab in a Danish nationwide cohort with moderate-to-severe AD up to 104 weeks exposure.
Objective: To identify predictors of flare in a 2-year follow-up study of patients with rheumatoid arthritis (RA) in sustained clinical remission tapering towards withdrawal of biological disease-modifying anti-rheumatic drugs (bDMARDs).
Methods: Sustained clinical remission was defined as Disease Activity Score for 28 joints (DAS28)-C reactive protein (CRP) ≤2.6 without radiographic progression for >1 year.
Objective: Successful uptake of biosimilars in rheumatology is limited by lack of real-world evidence regarding effectiveness of biosimilar-to-biosimilar switching. We investigated infliximab biosimilars CT-P13-to-GP1111 switching among patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA).
Methods: Observational cohort study from the DANBIO registry.
Aims: In May 2020, a nationwide, web-based system for remote entry of patient-reported outcomes (PROs) in inflammatory rheumatic diseases was launched and implemented in routine care (DANBIO-from-home). After 1.5 years of use, we explored clinical characteristics of patients who did versus did not use the system, and the time to first entry of PROs.
View Article and Find Full Text PDFObjective: To explore anxiety and self-isolation in patients with inflammatory rheumatic disease (IRD)15 months into the coronavirus disease 2019 (COVID-19) pandemic, including attitudes toward and effects of SARS-CoV-2 vaccination.
Methods: A nationwide online survey was conducted at 3 timepoints: May 2020, November 2020, and May 2021. Patients with IRD followed in the Danish Rheumatology Quality Registry (DANBIO) were asked about the effects of the pandemic, including SARS-CoV-2 infection and their behavior, anxiety, and concerns.
Objective: TURKBIO registry, established in 2011, is the first nationwide biological database in Turkey. This study aimed to provide an overview of TURKBIO data collected by June 2018.
Methods: The registry included adult patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), nonradiographic axial spondyloarthritis (nr-AxSpA), and psoriatic arthritis (PsA).
Objective: The objective of this study was to use daily data collected via a smartphone app for characterization of patient-reported and symptom-based (using an a priori definition) flares in an adult idiopathic inflammatory myopathy (IIM) cohort.
Methods: UK adults with an IIM answered patient-reported outcome measurements (PROMs) daily via a smartphone app during a 91-day study. Daily symptom PROMs addressed global activity, overall pain, myalgia, fatigue, and weakness (on a 0-100 visual analogue scale).
Background: The accumulation of risk for the development of rheumatoid arthritis (RA) is regarded as a continuum that may start with interacting environmental and genetic factors, proceed with the initiation of autoimmunity, and result in the formation of autoantibodies such as anti-citrullinated peptide antibodies (ACPA). In parallel, at-risk individuals may be asymptomatic or experience joint pain (arthralgia) that is itself non-specific or clinically suspicious for evolving RA, even in the absence of overt arthritis. Optimal strategies for the management of people at-risk of RA, both for symptom control and to delay or prevent progression to classifiable disease, remain poorly understood.
View Article and Find Full Text PDFEstablished risk loci for systemic lupus erythematosus at NCF2, STAT4, TNPO3, IRF5 and ITGAM associate with distinct clinical manifestations: A Danish genome-wide association study.
Joint Bone Spine
July 2022